Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized Clinical Study of the Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) With Thalidomide

NCT06231680 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT06231680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06231680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized Clinical Study of the Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) With Thalidomide
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 19, 2024
Completion date
September 30, 2025
Enrollment
132 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal carcinoma, lung cancer, nonsmall cell